New Zealand Companies Out of the 'Chillybin'
Client Alert | less than 1 min read | 08.19.15
On August 12, the U.S. in a Federal Register notice confirmed that it "has agreed to waive discriminatory purchasing requirements for eligible products and suppliers of New Zealand beginning on August 12, 2015," due to the WTO's approval of New Zealand as a member of the WTO Agreement on Government Procurement (GPA). Joining the 43-member GPA will provide new access to the U.S. federal marketplace for New Zealand-based companies, including "designated country" status under the Trade Agreements Act, and will open immediate doors to federal government contracting opportunities, including GSA and VA Schedule contracts, that generally limit acquisition to end products that are manufactured or substantially transformed in the U.S. or a "designated country."
Contacts
Insights
Client Alert | 4 min read | 09.16.26
CMS Offers Guidance as Scrutiny Rises Over ABA Therapy in Medicaid
Between 2021 and 2025, Medicaid spending on ABA therapy grew six times faster than the number of children who received services, making it one of the fastest-growing areas of Medicaid expenditure, according to CMS. On August 4, 2026, CMS released a toolkit to help state Medicaid and CHIP agencies strengthen their programs and limit fraud, waste, and abuse tied to increased demand for ABA therapy. In 2025, Medicaid spent about $10 billion on ABA and related therapy services for children with ASD — a dramatic increase from the $2 billion spent in 2021.
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development



